Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EPS (Basic): 2016-2024

Historic EPS (Basic) for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$3.69.

  • Crinetics Pharmaceuticals' EPS (Basic) fell 43.75% to -$1.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.52, marking a year-over-year decrease of 21.83%. This contributed to the annual value of -$3.69 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported EPS (Basic) of -$3.69 as of FY2024, which was down 0.00% from -$3.69 recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year EPS (Basic) high stood at -$2.42 for FY2020, and its period low was -$3.69 during FY2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$3.69 (2024), whereas its average is -$3.51.
  • Data for Crinetics Pharmaceuticals' EPS (Basic) shows a maximum YoY dropped of 17.14% (in 2023) over the last 5 years.
  • Crinetics Pharmaceuticals' EPS (Basic) (Yearly) stood at -$2.42 in 2020, then fell by 15.70% to -$2.80 in 2021, then declined by 12.50% to -$3.15 in 2022, then fell by 17.14% to -$3.69 in 2023, then remained steady at -$3.69 in 2024.